Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Miransertib |
Trade Name | |
Synonyms | ARQ-092|ARQ092|ARQ 092 |
Drug Descriptions |
Miransertib (ARQ092) is a pan-AKT inhibitor, resulting in inhibition of the PI3K/AKT signaling pathway and cell proliferation (PMID: 26469692, PMID: 31058421). |
DrugClasses | Akt Inhibitor (Pan) 21 |
CAS Registry Number | 1313881-70-7 |
NCIT ID | C99172 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AZD0156 + Miransertib | AZD0156 Miransertib | 2 | 0 |
GSK2334470 + Miransertib | GSK2334470 Miransertib | 2 | 0 |
KU-57788 + Miransertib | KU-57788 Miransertib | 2 | 0 |
Miransertib | Miransertib | 24 | 2 |
Miransertib + OSU-T315 | Miransertib OSU-T315 | 2 | 0 |
Miransertib + Paclitaxel | Miransertib Paclitaxel | 0 | 0 |
Miransertib + Sirolimus | Miransertib Sirolimus | 1 | 0 |
Miransertib + Torin 1 | Miransertib Torin 1 | 1 | 0 |
Miransertib + Trametinib | Miransertib Trametinib | 1 | 0 |
Miransertib + Trastuzumab | Miransertib Trastuzumab | 0 | 0 |